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Abstract
Background: Human papillomavirus (HPV) vaccines are indicated for the prevention of cancers and genital warts
caused by vaccine-covered HPV types. Although the standard regimen requires a two or three-dose vaccine series,
there is emerging data suggesting that a single dose of the bivalent or quadrivalent HPV vaccine generates persistently
positive antibody titers. No similar data is yet available for the nonavalent HPV vaccine, currently the only HPV vaccine
available in the United States. The overall objective of our study is to assess the stability and kinetics of antibody titers
for 24months following a single dose of the nonavalent HPV vaccine among preteen girls and boys.
Methods: This is a prospective, single-arm, open-label, non-randomized, Phase IIa trial among 9–11 year-old girls and
boys to determine the immunogenicity after a single dose of the nonavalent HPV vaccine (GARDASIL® 9) over 24months,
with a deferred booster dose at 24months and an optional booster at 30months after the first dose. Participants provide
blood specimens at 6, 12, 18, 24, and 30months after the first dose. Serologic geometric mean titers (GMT) of the nine
vaccine types (HPV 16/18/ 6/11/31/33/45/52/58) will be measured at each time point. The primary objective is to
determine the stability of type-specific serologic GMT of HPV16 and HPV18 between the 6- vs. 12-month, 12- vs.
18-month, and 18- vs. 24-month visits. Secondary objectives are to determine the stability of type-specific serologic
GMT of the other HPV types (HPV 6/11/31/33/45/52/58) between the visits and to assess safety and reactogenicity after
each vaccine dose.
Discussion: Single dose HPV vaccination could simplify the logistics and reduce costs of HPV vaccination in the US
and across the world. This study will contribute important immunogenicity data on the stability and kinetics of type-
specific antibody titers and inform feasibility of the single dose HPV vaccination paradigm.
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Cervical cancer
Background
Persistent oncogenic human papillomavirus (HPV) in-
fection is the obligate precursor for cervical cancer and
is associated with the development of several anogenital
cancers as well as oropharyngeal cancers in both women
and men. Although more than 200 types of HPV have
been identified, only a handful (between 13 and 15)
types are considered oncogenic (‘high-risk’); 70% of cer-
vical cancers are attributable to HPV type 16 (‘HPV16’)
and type 18 (‘HPV18’) [1]. Although non-oncogenic
(‘low-risk’), HPV types 6 and 11 are associated with sub-
stantial clinical, financial, and psychosocial burden of ex-
ternal genital warts [2].
Three HPV vaccines have been licensed for use in
the U.S., including the bivalent vaccine (Cervarix®,
GlaxoSmithKline Biologicals) targeting two HPV types
(HPV16 and 18), the quadrivalent vaccine (Gardasil®, Merck
and Co., Inc.) targeting four HPV types (HPV16, 18, 6, and
11) and the nonavalent vaccine (Gardasil® 9, Merck and Co.,
Inc.) targeting nine HPV types (HPV16, 18, 6, 11, 31, 33, 45,
52, and 58). These vaccines are non-infectious subunit
vaccines that contain virus-like particles (VLP) of respective
HPV types. The standard regimen requires a two or three-
dose vaccine series over 6 to 12months, depending on the
age of the patient. Recent evidence from vaccination pro-
grams in countries (e.g., Australia) with high vaccine uptake
and series completion rates suggests population-based
reduction in rates of vaccine HPV types, HPV-related pre-
cancerous lesions, and genital warts in both vaccinated
age-cohorts as well as herd immunity effects in unvaccin-
ated populations [3]. Yet, in the United States, both the
HPV vaccine uptake rates and rates of completion of the
two- or three-dose vaccine series continue to lag behind.
Recent data from the Centers for Disease Control and Pre-
vention (CDC) suggest that only 37% of the target-age ado-
lescents have completed the recommended vaccine series
schedules [4], with most receiving vaccine doses outside of
the recommended windows of the prescribed schedule. The
barriers to implementation in developing countries are even
greater, considering the high cost and logistical difficulties of
multiple dose schedule [5].
Emerging data suggests that a single dose of HPV vaccine
may induce a sufficiently strong immunogenic response to
elicit a degree of clinical protection. Post-hoc analyses in
the Costa Rica Vaccine Trial, a Phase III efficacy trial of the
bivalent HPV vaccine in women age 18 to 25 years,
showed that the vaccine efficacy against 12-month
persistent HPV16/18 infection was similarly high
among women who received one, two, or the recom-
mended three doses of the vaccine [6] and the antibody
levels following one-dose remained stable from month 6
through month 84 [7]. For the quadrivalent HPV vaccine,
similar data is available from a study in India examining
two- versus three-dose vaccine schedules among fe-
males aged 10–18 years. The study was prematurely
halted, allowing post-hoc analyses of participants re-
ceiving only one dose. Although antibody titers in those re-
ceiving one dose were lower than those receiving two- or
three-doses, antibody titers against all four vaccine types
(HPV 16/18/6/11) among one-dose recipients were higher
than the seropositivity cut-off levels of titers defined for a
protective natural immune response, and these titers were
stable and persistent up to 48months post-vaccination [8].
Incident and persistent HPV16 and 18 infections up to 7
years of follow-up were similar and uniformly low regard-
less of the number of vaccine doses received [9]. Specific
structure features of the VLP and unique features of the
virus life cycle are plausible biological mechanisms respon-
sible for the unexpected potency of one dose of these vac-
cines [10]. These data raise interesting prospects for
potential efficacy of single dose vaccine schedules, and raise
hopes for substantial cost savings and logistical simplifica-
tions for HPV vaccine implementation across the globe.
However, it is not known whether a single dose of the
nonavalent HPV vaccine, the only HPV vaccine available in
the United States, will exert a similarly persistent immuno-
genic response as shown in the studies of the bivalent or
quadrivalent HPV vaccines. In addition, it is important to
understand if two- or three-dose vaccine schedules with
doses received outside the recommended window (often
delayed) would induce protection similar to the recom-
mended schedules. We are currently conducting a clinical
trial of a nonavalent prophylactic HPV vaccine (GARDA-
SIL® 9) among pre-teen girls and boys in the United States
to add proof-of-principle evidence for these unanswered
questions. This paper discusses the study design, rationale,
and protocol of this HPV vaccine immunogenicity trial.
Methods
Study design and objectives
This is a Phase IIa, single-arm, open label, non-randomized
trial of a nonavalent prophylactic HPV vaccine among
9–11-year-old girls and boys to determine the stability
and kinetics of antibody titers induced after a single
Zeng et al. BMC Cancer          (2019) 19:290 Page 2 of 8
dose over 24 months, with a deferred-booster dose at
24months and optional booster at 30months. Participants
provide blood specimens at 6, 12, 18, 24, and 30months
after the first dose. Serologic geometric mean titers
(GMT) of the nine vaccine types (HPV 16/18/ 6/11/31/
33/45/52/58) will be measured at each collection time.
The primary objective is to determine the stability of
type-specific serologic GMT of HPV16 and HPV18 be-
tween the 6- vs. 12-month, 12- vs. 18-month, and 18- vs.
24-month visits. Secondary objectives are to determine
the stability of type-specific serologic GMT of the other
HPV types (HPV 6/11/31/33/45/52/58) between the visits
and to assess safety and reactogenicity after each vaccine
dose. The study hypothesis is that a single dose of the
nonavalent HPV vaccine will induce persistent and stable
serological responses for up to 24months to all 9 vaccine
HPV types. This study is being conducted among partici-
pants from the youngest of the licensed ages (9–11 years)
such that very few, if any, of these participants will have
become sexually active within the two year period before
their deferred booster dose. In addition, younger age chil-
dren are likely to mount higher immune titers [11] and
the immune responses to a single dose or two doses of the
HPV vaccines among girls aged 9–14 years appear to be
comparable to antibody responses of 3 doses in young
women 15–25 years old [12].
We have targeted an accrual of a total of 200 partici-
pants (143 girls and 57 boys) to receive the vaccine inter-
vention. With an anticipated attrition rate of 30%, we
expect to have at least 100 girls and 39 boys to complete
the study with evaluable results.
Study setting, funding, and regulatory approvals
This is a multi-institutional trial sponsored by the National
Cancer Institute (NCI) and conducted at the University of
Arizona (UA) and University of California Los Angeles
(UCLA). The protocol, consent/assent form and all recruit-
ment materials have been reviewed and approved by the
study sponsor and NCI Central Institutional Review Board
(CIRB) (protocol #UAZ 2015-05-01). All changes to the
protocol, consent/assent form and recruitment materials
are also reviewed and approved by the study sponsor and
NCI CIRB. Protocol date and version identifiers are listed
in Additional file 2. The US Food and Drug Administration
(FDA) has deemed this study of a licensed HPV vaccine to
be exempt from requirements of an investigational new
drug (IND) application. This clinical trial is registered in
ClinicalTrials.gov. All items from the World Health
Organization Trial Registration Data Set are listed in
Additional file 1.
Eligibility criteria
Study participants include healthy 9–11-year-old girls
and boys recruited from the institutional pediatric clinics
and collaborating community pediatric clinics at UA and
UCLA. Participant exclusion criteria include: previous
vaccination against HPV; use of any investigational agent
within 30 days preceding the first dose of the study vaccine
or during the study period; receiving chronic administration
of immunosuppressive agents or other immune-modifying
drugs or chemotherapeutic agents within six months prior
to the first vaccine dose; receiving active treatment for
cancer or autoimmune conditions; having confirmed or
suspected immunosuppressive or immunodeficient condi-
tion; having known bleeding disorders that preclude intra-
muscular injection; having acute or chronic, clinically
significant pulmonary, cardiovascular, hepatic or renal dys-
function which in the opinion of the investigator precludes
administration of the study vaccine; having a history of
allergic reactions attributed to compounds of similar chem-
ical or biologic composition of GARDASIL® 9, including
yeast allergy; or if participant is pregnant.
Study procedures
A schedule of study procedures is presented in Table 1.
Participants undergo a pre-study screening evaluation.
The legal representative(s) (most often parents and legal
guardians) of the participants is required to sign the in-
formed consent form and medical records release form.
Participants are asked to sign an assent form. Model
consent and assent forms are included in Additional file 3.
Participants and their legal representative(s) are inter-
viewed for the participant’s medical history (including
age of menarche) and concomitant medication use. Par-
ticipants are assessed for height, weight, vital signs
(temperature, pulse, and blood pressure), and baseline
signs and symptoms. Urine pregnancy test is performed
on participants who have started menstrual periods. The
legal representative(s) complete a questionnaire to col-
lect information on the participant’s parental education
attainment and household income.
Eligible participants and their legal representative(s)
return to the clinic for a baseline visit. When feasible,
this visit is combined with the pre-study screening
evaluation visit. If the baseline visit occurs more than
30 days from the screening visit, participants are reas-
sessed for weight and vital signs. Adverse events and
concomitant medications are reviewed and age at me-
narche and urine pregnancy test, if applicable, are
reassessed at the baseline visit unless it occurs on the
same day as the screening visit. If a urine pregnancy
test is positive, the participant is considered off-study
and does not undergo additional study procedures, in-
cluding vaccination. A baseline blood sample is col-
lected and participants are offered topical anesthetic
cream to be applied to the blood collection site prior
to the venipuncture. The blood samples undergo
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on-site serum separation and serum aliquots are
stored at − 80 °C until analysis.
Following the blood collection, participants receive the
priming injection of GARDASIL® 9. Participants are ob-
served in the clinic for at least 15min following vaccine ad-
ministration. Participants and legal representative(s) are
instructed to record any illness or injury for two weeks fol-
lowing the vaccine injection, and the diary is mailed back to
the study office in a pre-stamped and addressed envelope.
Participants and their legal representative(s) return to
the clinic at 6, 12, 18, 24, and 30months after the priming
injection of Gardasil 9. Blood samples are collected from
the participants at each visit and processed/stored as the
baseline samples. Similarly, participants are offered topical
anesthetic cream prior to blood collection. At all visits,
participants are assessed for adverse events, concomitant
medications, and menarche, if applicable. Weight and
height are assessed at the months 12 and 24 visits. For the
month 24 and 30 visits, participants also undergo a urine
pregnancy test, if applicable. If a urine pregnancy test is
positive, the participant is considered off-study and does
not undergo additional study procedures, including vac-
cination. Following the blood collection at the month 24
visit, participants receive the (deferred) booster injection
of GARDASIL® 9. At the month 30 visit, the third vaccine
dose is offered after the blood collection but is optional.
Participants keep a diary of any illness or injury for 2
weeks after each vaccine dose and mail the diary back to
the study office in a pre-stamped and addressed envelope
provided by the study office.
Participants and their legal representatives are contacted
monthly and within two weeks prior to each visit using
their preferred method of contact to promote participant
retention. Participants and their legal representatives are
reminded to refrain from non-study HPV vaccination dur-
ing the study period.
Dose modification
At the discretion of the study physician, the vaccine in-
jection may be delayed because of a current or recent
febrile illness. Low-grade fever itself (temperature < =
100.4) and mild upper respiratory infection are not gener-
ally contraindications to vaccination. Participants who de-
velop anaphylactic reactions following the first injection
will permanently discontinue Gardasil 9.
Off-agent criteria
Participants may stop receiving study agent for the fol-
lowing reasons: completed the protocol-prescribed pro-
cedures, adverse event or serious adverse event, received
an HPV vaccine outside the context of the study, inad-
equate agent supply, noncompliance, concomitant medi-
cations, and medical contraindication. Participants will
continue to be followed, if possible, for safety reasons
and in order to collect endpoint data according to the
schedule of events.
Off-study criteria
Participants may go ‘off-study’ for the following reasons:
the protocol procedures and any protocol-required fol-
low-up period is completed, adverse event/serious ad-
verse event, lost to follow-up, non-compliance,
concomitant medication, medical contraindication, with-
draw consent, death, determination of ineligibility (includ-
ing screen failure), pregnancy, or have received HPV
vaccine outside the context of the study.
Data management
Participant data are collected using protocol-specific case
report forms (CRF) developed utilizing NCI-approved
Common Data Elements (CDE). This study uses the
OnCore from Forte Research Systems, Inc. for data col-
lection, reporting and management. Study staff entering
data or reviewing data will have appropriate education,
training and experience to perform assigned tasks. A
quality assurance/quality control plan is implemented
to ensure protocol adherence to all aspects of the trial,
including obtaining informed consent, verification of
eligibility, adherence to protocol, documentation of ad-
verse events, accuracy of transcription between source
and CRF, and reporting serious adverse events.
In addition, representatives from the study sponsor
conduct annual monitoring visit to review regulatory doc-
uments for the study, verify that a signed/dated informed
consent is on file for each enrolled participant, review
documentation for all reported serious adverse events,
visit the Investigational Drug Pharmacy to assess drug
accountability, and review participant charts.
Data and safety monitoring
All adverse events (AEs) are assessed according to
NCI’s Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0. The study staff are trained and
follow good clinical practice (GCP) guidelines. The
University of Arizona Cancer Center (UACC) Data and
Safety Monitoring Board (DSMB) provides oversight
for subject safety consistent with the National Institutes
of Health (NIH) Policy for Data and Safety Monitoring
(policy dated June 10, 1998; further guidance statement
issued by the NIH on June 5, 2000) and the policy for
data and safety monitoring by the Data and Safety
Monitoring Boards. The UACC DSMB reviews the
study safety data quarterly.
Confidentiality and dissemination
All efforts are made to ensure clinical data integrity and
security and subject confidentiality. Each subject who
enters the study is assigned a subject identification
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number. This number is used to link data collection forms
to the subject’s identity. No reference is made to specific
subjects by name in any report or publication to maintain
confidentiality. The final trial dataset will be submitted to
the study sponsor at study conclusion. Public access to the
full protocol, participant level dataset, and statistical code
will be granted according to the policy set forth by the
NCI. The trial results will be reported to ClinicalTrials.gov
and published in peer-reviewed journals.
Laboratory analysis
Laboratory measurement of type-specific serologic GMTs
will be accomplished with a validated VLP enzyme-linked
immunosorbent assay (ELISA), which measures neutraliz-
ing and non-neutralizing IgG antibodies [13, 14]. This assay
has been shown to have high concordance with other HPV
antibody measurement approaches, including the competi-
tive Luminex immunoassay (cLIA) and pseudovirion-based
neutralization assays [15].
Statistical considerations
The primary endpoints are the persistence and stability
of serologic geometric mean titer (GMT) of HPV16 and
HPV18 between 6, 12, 18, and 24 months after the first
dose, prior to the administration of the second dose. A
one-sided paired t test will be performed to compare the
difference in the mean of the log-transformed type-specific
antibody levels between 6- and 12-month visits, between
12- and 18-month visits, and between 18- and 24-month
visits respectively, to evaluate whether the type-specific
GMT at 12−/18−/24-months, respectively, is not inferior to
the GMT at 6−/12−/18-months. Comparing the difference
in the mean of the log-transformed type-specific antibody
levels is equivalent to comparing the logarithm of the ratio
of GMTs since GMT is equal to the exponentiation of
log-transformed mean. Bonferroni correction will be used
to correct for multiple comparisons.
The protocol was originally designed to assess the sero-
logic response in girls. Addition of a cohort of boys was
included in a subsequent protocol expansion amendment.
Due to limits in the study completion timelines and avail-
able study budgets, fewer boys than girls are included in
the study to generate pilot data on the serologic response
in boys. We expect boys and girls to have different re-
sponses to the vaccine and will perform the primary ana-
lyses for girls and boys separately. For girls, with a sample
size of 100 and an overall significance level of 5% (based
on Bonferroni correction, i.e. a 1.67% significance level for
each test), there will be at least 90% power to detect a
non-inferiority margin no greater than 0.35 standard devi-
ations [16]. For boys, with a sample size of 39 and an over-
all significance level of 5%, there will be at least 80%
power to detect a non-inferiority margin no greater than
0.50 standard deviations. In addition, similar to the
analysis performed by Safaeian et al. [17], we will also
evaluate the stability by categorizing the changes in anti-
body level from 6months to 12months. Specifically, a par-
ticipant’s antibody level at 12months either remains
within two-fold of the level at 6months (considered as
stable) or decreases/increases more than two-fold of the
level at 6months (same for the changes from 12months
to 18months and from 18months to 24months). Percent-
age of participants whose type-specific antibody levels de-
crease, increase, or remain stable between the 6- and
12-month study visits, between the 12- and 18-month
study visits and between the 18- and 24-month study
visits will be reported along with the associated 95% confi-
dence interval. For girls, a sample size of 100 will produce
a two-sided 95% confidence interval with a width ≤ 0.203
based on the exact method approach. For boys, a sample
size of 39 will produce a two-sided 95% confidence inter-
val with a width ≤ 0.328 based on the exact method
approach.
HPV 16/18 was singled out for the primary endpoints
since it will allow direct comparisons with similar data
on type-specific antibody level stability and kinetics from
the types present in both the bivalent and quadrivalent
vaccines. We were also interested in examining the persist-
ence and stability of serologic GMT of the other HPV types
covered by the nonavalent HPV vaccine (i.e., HPV types 6,
11, 31, 33, 45, 52, and 58). As obesity has been associated
with lower antibody levels in other vaccines [18, 19], we
propose to perform a linear mixed effects model with body
mass index (BMI), time, and the interaction between BMI
and time as the covariates on antibody level data measured
at 6, 12, 18, and 24months.
Similar to the primary analyses, we will perform all of
the secondary and exploratory analyses separately for
girls and boys. For the secondary and exploratory ana-
lyses, adjustment for multiple comparisons will not be
performed. However, the number of comparisons will be
reported and we will cautiously interpret the findings.
For both primary and secondary endpoints, if the nor-
mality assumption is violated, potential transformation
will be sought or nonparametric methods such as signed
rank test will be performed.
We will try to reduce the fraction of participants with
missing outcomes as much as possible. The covariates
(e.g. BMI, body surface area, and sociodemographics)
that are predictive of missing-ness for each outcome at each
visit (i.e., 6, 12, 18 and 24months) will be identified through
use of logistic regression for each missing indicator and
then incorporated into multiple imputation procedures to
handle missing data while performing the statistical analysis
for both primary and secondary endpoints.
No formal interim statistical analyses are planned for
this trial. Accrual, data collection, and any adverse events
will be monitored on a regular basis.
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Discussion
The trial was opened to accrual in March 2016 and
reached its accrual target in July 2017, ahead of schedule
(see Fig. 1). The study follow-up and retention efforts
are ongoing and the last participant is expected to
complete the final study visit in February 2020.
Different operational models for recruitment and
study conduct were employed at the two study centers.
Participants at UCLA were accrued mostly by study
pediatricians informing patients/guardians receiving rou-
tine care at the institutional pediatric clinic about the
study. Study visits at UCLA are also conducted at the
same clinic. Participants at UA were initially accrued by
flyers at the institutional pediatric clinic and at a local
private community pediatric clinic. Subsequently, guard-
ians/parents of age eligible patients seen in the institu-
tional pediatric clinic were contacted by the clinic staff
to obtain permission to contact by the study staff which
has greatly improved study accrual. Participants and
their guardians come to a UA satellite cancer prevention
clinic for study visits. Even though different models were
implemented for recruitment and study conduct at the
two study centers, both have worked efficiently.
As of October 2018, the study has a retention rate of 89
and 99% for girls, and 93 and 100% for boys at UA and
UCLA, respectively. The high retention rate is attributed to
the regular contact made by the study staff with the study
participants and/or their legal representative(s). Conducting
the study visits where patients receive routine care, and be-
ing referred by a trusted, primary care provider may have
attributed to the 99–100% retention for UCLA participants.
To provide rigorous, long-term data to support one-
dose HPV vaccine recommendations if warranted, there
are ongoing efforts to extend the follow-up of the
one-dose recipients from the original Costa Rica HPV
Vaccine trial, to conduct a randomized, controlled, efficacy
trial (NCT03180034) of one or two doses of the bivalent
or nonavalent vaccines, and to perform one-dose immu-
nobridging studies [7]. Our study is expected to inform
the stability and kinetics of antibody responses of the nine
vaccine HPV types up to 24months after a single dose of
the nonavalent HPV vaccine in girls and boys 9–11 years
of age. This information will add to the ongoing efforts on
demonstrating evidence of efficacy of single dose HPV
vaccination for the prevention of HPV-attributed cancers
and diseases.
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